University of Colorado Cancer Center
Playback speed
10 seconds
Brigatinib vs Crizotinib in Advanced ALK+ NSCLC: A Glimpse Into the Future of the 1st-Line ALK Inhibitor Therapy?
By
University of Colorado Cancer Center
FEATURING
Ross Camidge
By
University of Colorado Cancer Center
FEATURING
Ross Camidge
1,116 views
February 5, 2020
Comments 0
Login to view comments.
Click here to Login
Videos